Amylin drug cuts weight up to 9.2% in diabetes trial
Zealand Pharma’s petrelintide delivered up to 9.2% weight loss over 28 weeks in people with obesity and type 2 diabetes, with few dropouts. Here is the figure that jumped out first. Just 1.9% of people taking petrelintide in a new Phase 2 trial stopped because of stomach-related side effects.
<p>Zealand Pharma’s petrelintide delivered up to 9.2% weight loss over 28 weeks in people with obesity and type 2 diabetes, with few dropouts. Here is the figure that jumped out first. Just 1.9% of people taking petrelintide in a new Phase 2 trial stopped because of stomach-related side effects. </p>